PTCT

Company Overview — What Does PTC THERAPEUTICS, INC. Do?

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. PTC THERAPEUTICS, INC. (PTCT) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Stuart W. Peltz and employs approximately 1,410 people, headquartered in South Flainfield, New Jersey. With a market capitalization of $5.7B, PTCT is one of the notable companies in the Healthcare sector.

PTC THERAPEUTICS, INC. (PTCT) Stock Rating — Reduce (April 2026)

As of April 2026, PTC THERAPEUTICS, INC. receives a Reduce rating with a composite score of 40.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PTCT ranks #2,283 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PTC THERAPEUTICS, INC. ranks #268 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PTCT Stock Price and 52-Week Range

PTC THERAPEUTICS, INC. (PTCT) currently trades at $68.69. The stock lost $2.16 (3.0%) in the most recent trading session. The 52-week high for PTCT is $87.50, which means the stock is currently trading -21.5% from its annual peak. The 52-week low is $35.95, putting the stock 91.1% above its annual trough. Recent trading volume was 588K shares, suggesting relatively thin trading activity.

Is PTCT Overvalued or Undervalued? — Valuation Analysis

PTC THERAPEUTICS, INC. (PTCT) carries a value factor score of 77/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 8.10x, compared to the Healthcare sector average of 23.63x — a discount of 66%. The price-to-sales ratio is 3.27x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PTCT trades at 6.52x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, PTC THERAPEUTICS, INC. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

PTC THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score

PTC THERAPEUTICS, INC. (PTCT) earns a quality factor score of 9/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -124.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 24.5% versus the sector average of -33.1%.

On a margin basis, PTC THERAPEUTICS, INC. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is 9.2% (sector: -66.1%). Net profit margin stands at -2.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 13.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PTCT Debt, Balance Sheet, and Financial Health

PTC THERAPEUTICS, INC. has a debt-to-equity ratio of -184.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.35x, indicating strong short-term liquidity. Total debt on the balance sheet is $286M. Cash and equivalents stand at $673M.

PTCT has a beta of 0.97, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for PTC THERAPEUTICS, INC. is 50/100, reflecting average volatility within the normal range for its sector.

PTC THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PTC THERAPEUTICS, INC. reported revenue of $1.76B and earnings per share (EPS) of $8.58. Net income for the quarter was $711M. Gross margin was 100.0%. Operating income came in at $884M.

In FY 2025, PTC THERAPEUTICS, INC. reported revenue of $1.73B and earnings per share (EPS) of $8.58. Net income for the quarter was $683M. Revenue grew 114.5% year-over-year compared to FY 2024. Operating income came in at $867M.

In Q3 2025, PTC THERAPEUTICS, INC. reported revenue of $211M and earnings per share (EPS) of $0.20. Net income for the quarter was $16M. Revenue grew 7.2% year-over-year compared to Q3 2024. Operating income came in at $3M.

In Q2 2025, PTC THERAPEUTICS, INC. reported revenue of $179M and earnings per share (EPS) of $-0.83. Net income for the quarter was $-65M. Revenue grew -4.2% year-over-year compared to Q2 2024. Operating income came in at $-35M.

Over the past 8 quarters, PTC THERAPEUTICS, INC. has demonstrated a growth trajectory, with revenue expanding from $187M to $1.76B. Investors analyzing PTCT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PTCT Dividend Yield and Income Analysis

PTC THERAPEUTICS, INC. (PTCT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PTCT Momentum and Technical Analysis Profile

PTC THERAPEUTICS, INC. (PTCT) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

PTCT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PTC THERAPEUTICS, INC. (PTCT) ranks #268 out of 838 stocks based on the Blank Capital composite score. This places PTCT in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PTCT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PTCT vs S&P 500 (SPY) comparison to assess how PTC THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.

PTCT Next Earnings Date

No upcoming earnings date has been announced for PTC THERAPEUTICS, INC. (PTCT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PTCT? — Investment Thesis Summary

The quantitative profile for PTC THERAPEUTICS, INC. suggests caution. The quality score of 9/100 flags below-average profitability. The value score of 77/100 suggests attractive pricing relative to fundamentals.

In summary, PTC THERAPEUTICS, INC. (PTCT) earns a Reduce rating with a composite score of 40.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PTCT stock.

Related Resources for PTCT Investors

Explore more research and tools: PTCT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PTCT head-to-head with peers: PTCT vs AZN, PTCT vs SLGL, PTCT vs VMD.